Canine CryoprecipitateThis page contains information on Canine Cryoprecipitate for veterinary use.
The information provided typically includes the following:
- Canine Cryoprecipitate Indications
- Warnings and cautions for Canine Cryoprecipitate
- Direction and dosage information for Canine Cryoprecipitate
Canine CryoprecipitateThis treatment applies to the following species:
FOR INTRAVENOUS USE IN DOGS ONLY
Caution: This blood component may only be used by or on the order of a licensed veterinarian.
Canine Cryoprecipitate Indications And Usage
Canine cryoprecipitate, lyophilized, is indicated for the treatment of inherited coagulopathies and von Willebrand’s crisis or prevention. Cryoprecipitate can also be used as a topical hemostatic in surgery or dental procedures. Administration of this product is a temporary means of support and not intended to permanently alleviate clinical signs of coagulopathies or von Willebrand’s crisis.
Canine cryoprecipitate is recommended for intravascular administration through either a Hemo-Nate (or equivalent) filter or standard blood administration set. Topical application is recommended to control bleeding during surgery or dental procedures. This solution may be administered in conjunction with or combined with whole blood, pRBCs, plasma, saline and glucose. The solution is isotonic when rehydrated. It is not recommended to co-administer this product with any blood product or IV fluid other than 0.9% sterile saline.
For IV administration, we recommend administration by syringe with an extension set and catheter. Specifically, connect the male end of the syringe into the female end of the Hemo-Nate filter. Connect the male end of the Hemo-Nate filter into the female end of the extension set. Administer at a rate of 2-5 ml/kg/hour based on recommended dosages. A small amount of 0.9% NaCl may be used to “flush” the cryoprecipitate through the extension set and into the catheter.
If this product is given as a pretreatment for coagulopathy before surgery, it should be given within two to four hours of the event. This dose may be repeated every thirty minutes during highly invasive surgical techniques to maintain normal coagulation.
Topical application is recommended to control bleeding during surgery or dental procedures.
The cryoprecipitate should be transferred by syringe and applied directly to the site of hemorrhage.
One vial of lyophilized cryoprecipitate has an approximate minimum equivalency to a 250-300 milliliter unit of fresh frozen plasma (FFP). There is no research confirmed standard dosage for cryoprecipitate but the current literature recommends an empiric dosage of 1 unit of cryoprecipitate obtained from a 250 ml bag of FFP for each 10-12 kilograms of body weight. Extrapolating equivalency dosages yields a dosage of one vial of lyophilized cryoprecipitate for every 12 kilograms of body weight. As the severity of coagulaopathy’s varies between patients, it is up the clinician’s careful judgment to determine an appropriate dose for each individual patient.
Product should sit at room temperature for 5-10 minutes before adding diluent. Do not use needles larger than 20 GA as septum coring may result. Canine cryoprecipitate, lyophilized, should be rehydrated by adding 70ml of 0.9% sterile saline. Mix by swirling and gentle inversion of the product until all powder is rehydrated. Once diluent is added, the vial may be warmed in a 37°C (98.6°F) water bath to speed rehydration. Put in water tight plastic bag to protect injection port. DO NOT EXCEED 15 MINUTES IN 37°C OR TEMPERATURES GREATER THAN 37°C.
A history of anaphylaxis to plasma containing products is a contraindication for use. If necessary, minor crossmatch should be performed to support compatibility.
Warnings And Precautions
This product must be used within twenty-four (24) hours of rehydration to assure stability of the coagulation factors, particularly factor VIII.
Do to the delicate nature of clotting factors it is recommended that this product be rehydrated immediately before use. Allowing it to sit in a rehydrated state, over time, will result in decreased potency due to clotting factor degradation.
DO NOT use sterile water for rehydration of this product.
This product is made from source canine donor plasma. As with all blood products and components there is a risk of infectious disease. The risk has been minimized by prescreening donors and carefully monitoring for bacterial and fungal growth through culture and endotoxin evaluation during processing. All source plasma must meet in-house infectious disease standards which includes donors free of Dirofilaria, Lyme, Babesia, Anaplasma, Ehrlichia, Rocky Mountain Spotted Fever, Hepatozoon, Leishmania, Neorickettsia, Bartonella and hemotropic Mycoplasmas (Mycoplasma haemocanis and Candidatus mycoplasma haematoparvum). However, owners of patients should be made aware of the use of cryoprecipitate and its possible side effects. All infections thought by a veterinarian possibly to have been transmitted by administration of this product should be reported to the Department of Veterinary Services at Animal Blood Resources International, 1-800-243-5759.
Potential reactions to canine cryoprecipitate in recipient dogs may include nausea, peripheral vasodilation and urticaria. Individual anaphylactic reactions cannot be ruled out but are considered extremely rare.
Canine cryoprecipitate, lyophilized, is made from a controlled thaw of source pooled fresh frozen plasma from active donors in the ABRI donor population. It is a sterile, nonpyrogenic white to pale amber powder. It contains a concentration of the cold insoluble portion of plasma containing approximately 50% Factor VIII, 20% fibrinogen and some Factor XIII, vWF and VIIIc. More specifically, each 70 m reconstituted unit contains a minimum of 150 mg fibrinogen, 80 IU von Willebrand’s factor and 80 IU Factor VIII derived from a 250-300 ml equivalent unit of canine fresh frozen plasma. It is produced without preservative. All source plasma must meet CDFA and in-house infectious disease standards. Canine cryoprecipitate does not contain DEA isoagglutins; therefore, blood typing is not required prior to administration. If the patient has received multiple plasma transfusions, a minor crossmatch is recommended to support compatibility.
This product is shipped refrigerated or frozen. Canine cryoprecipitate should be stored at 4-6°C (refrigerated) until use. Product, before rehydration, is stable for 18 months as labeled.
Refrigerated storage of rehydrated product is required if the product will not be administered within two hours. Rehydrated product should be discarded after 24 hours as stability of the coagulation factors cannot be validated beyond 24 hours.
Canine Cryoprecipitate is prepared and supplied by Animal Blood Resources International, PO Box 609, Stockbridge, MI 49285
NAC No.: 13980083
P.O. BOX 1118, DIXON, CA, 95620-1118
|Every effort has been made to ensure the accuracy of the Canine Cryoprecipitate information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the US product label or package insert.|
Copyright © 2014 North American Compendiums. Updated: 2014-04-11